| 鳞状非小细胞肺癌的病理特征和治疗药物研究进展 |
| |
| 引用本文： | 许丽萍.鳞状非小细胞肺癌的病理特征和治疗药物研究进展[J].微生物学杂志,2016(11). |
| |
| 作者姓名： | 许丽萍 |
| |
| 作者单位： | (1. 湖州市第一人民医院药剂科,浙江 湖州 313000;2. 湖州市第一人民医院呼吸内科,浙江 湖州 313000) |
| |
| 摘 要： | 鳞状非小细胞肺癌(sq-NSCLC)约占非小细胞肺癌(NSCLC)病例的 30%,其治疗难、预后差,是一种毁灭性的肺癌类型, 转移性 sq-NSCLC 的 5 年生存率不足 5%。近 20 年来,sq-NSCLC 治疗领域的进展甚微,尤其是一线治疗,导致该领域存在严重未满 足的临床需求,sq-NSCLC 患者迫切需要更多的新治疗方案。综述 sq-NSCLC 的临床病理特征和治疗药物的研究进展,为 sq-NSCLC 治 疗药物的深入研究与开发提供参考。
|
| 关 键 词： | 鳞状非小细胞肺癌 临床病理特征 治疗药物 |
Advances in Research on Clinicopathologic Features
and Medications of sq-NSCLC |
| |
| XU Liping.Advances in Research on Clinicopathologic Features
and Medications of sq-NSCLC[J].Journal of Microbiology,2016(11). |
| |
| Authors: | XU Liping |
| |
| Institution: | (1. Department of Pharmacy, The First Hospital of Huzhou, Huzhou 313000, China; 2. Department of Respiratory Medicine, The First Hospital of Huzhou, Huzhou 313000, China) |
| |
| Abstract: | Squamous-cell non-small cell lung cancer (sq-NSCLC) represents approximately 30% of NSCLC cases. As a devastating disease with a challenging treatment and poor prognosis, the 5-year-survival rate of metastatic sq-NSCLC is less than 5%. Over the past 20 years, little progress has been made in sq-NSCLC treatment, especially in the rst-line treatment, giving rise to unmet medical needs. Therefore, patients urgently need more new therapeutic schemes. The advances in key clinicopathologic features and medications of sq-NSCLC were reviewed to provide references for further researches. |
| |
| Keywords: | sq-NSCLC clinicopathologic feature medication |
|
| 点击此处可从《微生物学杂志》浏览原始摘要信息 |
| 点击此处可从《微生物学杂志》下载免费的PDF全文 |
|
